Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19 https://doi.org/10.1007/s11739-020-02585-9 Of 278 patients with Covid-19, 127 received prophylaxis with high enoxaparin doses and 151 with standard dosage. At 21 days, the incidence rate of death and clinical deterioration were… Continue reading "(04 Jan 2021) Enoxaprin- 60% reduction of mortality with higher doses"
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size https://doi.org/10.1016/j.biopha.2020.110825 This was a multicenter trial (ChiCTR2000030894 and NCT04310228) in adults with COVID-19. Patients were randomly assigned (3:1:1) to a 14-day combination of… Continue reading "(01 Jan 2021) Tocilizumab- TCZ with or without favipiravir can effectively improved the pulmonary inflammation of COVID-19 patients"
Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study https://doi.org/10.1093/ofid/ofaa563 Among 315 patients with SARS-CoV-2 pneumonia, 70 (22.2%) died during hospital stay. The composite endpoint was achieved by 114 (36.2%)… Continue reading "(29 Dec 2020) Heparin- LMWH was associated with a reduced risk of 30-day mortality"
Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial https://doi.org/10.1183/13993003.03725-2020 NCT04552483- In a multicenter, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and/or fatigue) were enrolled. After… Continue reading "(29 Dec 2020) Nitazoxanide- early nitazoxanide therapy was safe and reduced viral load significantly"
Tocilizumab in the Management of COVID-19: A Preliminary Report https://doi.org/10.1016/j.amjms.2020.11.005 A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020. Most patients were male (66.7%), Hispanic (63.3%)… Continue reading "(24 Dec 2020) Tocilizumab- 60.0% patients demonstrated clinical improvement"
